Skip to main content
ARDELYX, INC. logo

ARDELYX, INC. — Investor Relations & Filings

Ticker · ARDX ISIN · US0396971071 LEI · 549300F542QR4SXHCY32 US Manufacturing
Open in API
Filings indexed 1,078 across all filing types
Latest filing 2014-07-14 Regulatory Filings
Country US United States of America
Listing US ARDX

About ARDELYX, INC.

https://www.ardelyx.com/

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines to address unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Its key commercial product is XPHOZAH® (tenapanor), a novel mechanism therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Ardelyx also develops treatments for Irritable Bowel Syndrome with Constipation (IBS-C), aiming to advance patient care through its portfolio of innovative therapies.

Recent filings

Filing Released Lang Actions
S-8 Filing
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock incentive plans and employee stock purchase plans. It includes detailed information about the securities to be registered, the plans under which they are offered, and legal indemnification provisions. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content confirm it is a full filing, not just an announcement or certification.
2014-07-14 English
SC 13D Filing
Major Shareholding Notification
2014-07-01 English
4 Filing
Director's Dealing
2014-06-26 English
4 Filing
Director's Dealing
2014-06-26 English
4 Filing
Director's Dealing
2014-06-26 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content focuses on amendments to the company's Articles of Incorporation and Bylaws, effective upon the closing of the initial public offering. It details changes in corporate governance documents, such as share authorization, voting provisions, and board structure. There is no financial data or earnings information, nor is it a full annual or quarterly report. The document is not a proxy statement or a remuneration report. It is an announcement of changes in corporate governance documents and bylaws, which aligns with Board/Management Information filings. The length (5740 characters) and detailed description of governance changes support classification as MANG rather than a brief announcement or regulatory filing. Therefore, the document is best classified as Board/Management Information (MANG).
2014-06-24 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.